History of allergic disease or reactions likely to be exacerbated by any component of the IMP.Known hypersensitivity to any component of the IMP.Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Females of childbearing potential who are sexually active with a non-sterilised male partner must have used a highly effective method of contraception for at least 28 days prior to dosing with IMP and must agree to continue using such precautions until the Final Follow-up Visit. Able to complete the Follow-up Period through Day 361.Electrocardiogram without clinically significant abnormalities at screening.Healthy by medical history, physical examination, and baseline safety laboratory studies, according to the judgement of the PI.Weight ≥ 50 kg and ≤ 110 kg at screening, including a BMI of ≥ 18.0 to ≤ 30.0 kg/m^2.Negative SARS-CoV-2 qRT-PCR and/or serology tests prior to randomisation.Written informed consent and any locally required authorisation obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |